Metastatic Breast Cancer Treatment Market Segmentation by Treatment Type (Chemotherapy, Radiation Therapy, Biologic, Targeted Therapy, Breast Surgery, and Hormone Therapy); and by End-User (Hospitals, Clinics, Ambulatory Surgical Centres, and Others) – Global Demand Analysis and Opportunity Outlook 2021-2029
Buy Now
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
The Metastatic Breast Cancer Treatment Market is estimated to grow with a high CAGR during the forecast period, i.e., 2021-2029. The increasing prevalence of breast cancer globally, along with the growing recurrence rate of breast cancer is expected to fuel the development of this market. The growth of the market can also be attributed to factors such as the increasing geriatric population and an increase in exposure to cancer risk factors linked to social and economic development. Cancer is currently the second leading cause of death worldwide. According to the Globocan report, global cancer burden is estimated to have risen to 19.3 million cases and 10 million cancer-related deaths in 2020. According to Globocan report 2020, the incidence rate of breast cancer was 5.20% which accounted for 2.26 million new cases globally with a mortality rate of 6.9%. Such increasing prevalence of breast cancer is expected to drive the growth of global metastatic breast cancer treatment market.
The market is segmented based on treatment type into chemotherapy, radiation therapy, biologic, targeted therapy, breast surgery, and hormone therapy, out of which, chemotherapy and radiation therapy segment is anticipated to grab the largest share by the end of 2021 on account of its high level of specificity and lesser side-effects. Moreover, increasing government approval of new treatment & drugs globally is also projected to contribute to the growth of the segment during the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT
Based on end-user, the hospital segment held the largest share in the global metastatic breast cancer treatment market on the back of increasing patient influx and increasing spending by the hospitals on breast cancer treatments.
Ans: Rising prevalence of breast cancer and increasing investments in R&D are the key factors driving market growth.
Ans: The market is anticipated to attain a high CAGR over the forecast period, i.e., 2021-2029.
Ans: Lack of awareness and high risk associated with the radiation exposure are estimated to hamper market growth.
Ans: The market in Asia Pacific region will provide ample growth opportunities owing to rising geriatric population and increasing breast cancer prevalence.
Ans: The major players dominating the Metastatic Breast Cancer Treatment market are F. Hoffmann-La Roche Ltd, Merck & Company, Inc., AstraZeneca Plc., Novartis, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Limited, Johnson & Johnson, GlaxoSmithKline plc., and others.
Ans: The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by treatment type, end-user and region.
Ans: With respect to treatment type, the chemotherapy & radiation therapy segment is anticipated to hold the largest market share owing to the growing requirement for metastatic breast cancer treatment.
Submit Your Request For Proposal (RFP)
Submit RFP Buy Now Download Research Report Sample
